
    
      The relapsed/refractory AML patients will receive
      IA/DA/MA(I,Idamycin，D，Daunorubicin，M，Mitoxantrone，A，cytosine arabinoside) chemotherapy
      followed by infusion of high dose allogeneic mismatched hematopoietic stem cells.

      no graft-versus-host disease (GVHD) prevention will be conducted before transplantation.
      Cytokine storm,GVHD snd donor graft will be detected post-transplantation.
    
  